Liqi Huoxue dripping pill protects against myocardial ischemia-reperfusion injury via the PI3K/Akt/GSK-3β signaling pathway in rats

Background:Liqi Huoxue dripping pill(LQHXDP),a traditional Chinese drug for coronary heart disease,has a protective effect on the heart of rats with myocardial ischemia-reperfusion injury(MIRI)in previous studies;however,its mechanism of action remains unclear.The purpose of this study was to investigate the protective mechanism of LQHXDP on MIRI in rats and its relationship with the PI3K/Akt signaling pathway.Methods:In this study,Sprague-Dawley rats were pre-infused with LQHXDP(175 mg/kg/d)for 10 days.PI3K inhibitor LY294002(0.3 mg/kg)was intravenously injected 15 minutes before ischemia.The rat model of MIRI was established by ligating the left anterior descending coronary artery.Subsequently,cardiac hemodynamics,serum myocardial injury markers,inflammatory factors,myocardial infarct size,antioxidant indexes,myocardial histopathology,and phosphorylation levels of key proteins of PI3K/Akt signaling pathway were assessed in rats.Results:LQHXDP was found to improve cardiac hemodynamic indexes,reduce serum creatine kinase MB isoenzyme activity and cardiac troponin and heart-type fatty acid binding protein levels,lower serum interleukin-1 beta,interleukin-6 and tumour necrosis factorαlevels,reduce the myocardial infarct size and enhance the antioxidant capacity of myocardial tissue in MIRI rats.Pathological analysis revealed that LQHXDP attenuated the extent of myocardial injury and protected mitochondria from damage in MIRI rats.Immunoblot analysis revealed that LQHXDP increased the expression levels of p-Akt and p-GSK-3βin MIRI rat cardiomyocytes.PI3K inhibitor LY294002 could impair these effects of LQHXDP.Conclusion:LQHXDP attenuated myocardial injury,attenuated oxidative stress injury and reduced inflammatory response in MIRI rats,and its protective effects were mediated by activating of PI3K/Akt/GSK-3βsignaling pathway.

The Protective Effect of Compound Danshen Dripping Pills on Oxidative Stress after Retinal Ischemia/Reperfusion Injury in Rats

Objective: To investigate the effect of Compound Danshen Dripping Pills (CDDP) on oxidative stress after ischemia/reperfusion (I/R) injury in the rat retina. Methods: Adult male SD rats were randomly divided into 3 groups: sham (group A), I/R (group B), and I/R plus CDDP (group C). Retinal ischemia/reperfusion injury (RIRI) was introduced by increasing the intraocular pressure (IOP) to 110 mmHg for 60 min via cannulation into the anterior chamber. Right after the insult, CDDP was administered intragastrically (450 mg/kg/d) for 7 days. The levels of malondialdehyde (MDA), the activities of superoxide dismutase (SOD), glutathione peroxidase (GSH-Px), and catalase (CAT) in the retinal tissues were determined on d1 and d7 after the ischemic insult. Results: Following ischemia, the MDA levels in group B and group C were significantly higher than those in group A (p < 0.01). CDDP significantly lowered MDA levels in group C when compared with group B (p < 0.01). The activities of SOD, GSH-Px and CAT were higher in group A than in group B and group C (p < 0.01). CDDP could increase the activities of SOD, GSH-Px and CAT remarkably in group C when compared with group B (p < 0.01). Conclusion: CDDP can protect the retina from I/R injury through reducing oxidative stress, and thus may be a promising method for the treatment of ischemic retinal disorders.

Effect of Qishen Yiqi dripping pills combined with trimetazidine on the treatment of chronic heart failure: A meta-analysis

Objective:To systematically evaluate the safety and effectiveness of Qishen Yiqi dripping pills combined with trimetazidine in the treatment of chronic heart failure.Methods:A total of four English and Chinese electronic databases were searched:CNKI,VIP,CBM,PUBMED.Cochrane bias risk tools were used to assess the methodological quality of qualified studies.Meta-analysis was conducted by Review Manager 5.3.A total of 9 articles were included,with a total sample size of 855 cases,443 cases in the observation group and 412 cases in the treatment group.Results:Qishen Yiqi dripping pills combined with trimetazidine in the treatment of chronic heart failure has a total effective rate(RR=1.22,95%CI[1.15-1.30];p<0.00001),LVEF(MD=6.03,95%CI[5.39,6.67],P<0.00001),BNP(MD=-101.87,95%CI[-109.90,-93.83],P<0.00001),E/A(MD=-4.32,95%CI[-5.70,-2.93],P<0.00001),SYP(MD=-10.32,95%CI[-13.32,-7.32],P<0.00001),LVESD(MD=-5.50,95%CI[-6.03,-4.96],P<0.00001),6-MWT(MD=110.13,95%CI[96.89,123.36],P<0.00001)Adverse reactions occurred less frequently and did not affect treatment.Conclusion:This study shows that QYDP combined with TMZ can improve various indicators of CHF patients.However,due to the small sample size and the generally low quality of research,a more rigorous and reasonably designed RCT is needed to confirm these findings.

Clinical Intervention Effect of Compound Danshen Dripping Pills on Aspirin Resistant Patients with Coronary Heart Disease

[Objectives]To study the clinical intervention effect of Compound Danshen Dripping Pills on aspirin-resistant patients with coronary heart disease(CHD).[Methods]240 patients with coronary heart disease who took Aspirin were selected to measure thrombocytopenia by sonoclot.They were randomly divided into four groups:group A(n=60),Compound Danshen Dripping Pills and aspirin.group B(n=60),aspirin;group C(n=60),high dose aspirin;group D(n=60),Compound Danshen Dripping Pills.CR and PF were determined by sonoclot after one month.The incidence of angina pectoris,acute myocardial infarction,sudden cardiac death and hemorrhage were observed.[Results]After treatment,the CR and PF levels of group A and C were significantly lower than those before treatment,and there was no significant difference between group B and D and before treatment.After treatment,the levels of CR and PF in group A and C were significantly lower than those in group B and D,and there was a significant difference.Angina pectoris and myocardial infarction events in group D were significantly higher than the other four groups;hemorrhage events in group C were significantly higher than the other three groups.[Conclusions]Compound Danshen Dripping Pills combined with aspirin can be used as an economical,effective,and more dependent alternative to inhibit platelet activity in aspirin resistance,and can further reduce the occurrence of acute coronary events.

Integrated UHPLC-MS and network pharmacology to explore the active constituents and pharmacological mechanisms of Shenzao dripping pills against coronary heart disease

Background:Shenzao dripping pills(SZDP)is an empirical prescription of traditional Chinese medicine that is mainly used to treat coronary heart disease.However,the chemical composition and pharmacological mechanisms of SZDP are unknown.Methods:In this study,ultra-high performance liquid chromatography-quadruple-Exactive Orbitrap mass spectrometry was used to identify the chemical components in extracts and medicated plasma of SZDP.Subsequently,we performed network pharmacology methods,including target prediction by Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform and Integrative Pharmacology-based Research Platform of Traditional Chinese Medicine,protein-protein interaction network via STRING database;further,the key targets and compounds were screened using Cytoscape.Finally,the key targets and compounds were validated by molecular docking.Results:72 chemical constituents were identified from SZDP by high performance liquid chromatography and mass spectrometry technology.Among the components absorbed into plasma by SZDP,24 prototype components and 9 metabolized components were identified.The network pharmacology analysis of the prototype components showed that there are 13 key compounds(including ginsenoside Rc,Rb1,Rb2,ferulic acid,etc.),90 proteins(including proto-oncogene tyrosine-protein kinase Src,nuclear receptor subfamily 3 group C member 1,caspase-3,etc.),and 10 pathways(including estrogen,IL-17 and VEGF signaling pathway,etc.)that play an essential role in the treatment of coronary heart disease with SZDP.In addition,the results of molecular docking revealed that ginsenosides Rc,Rb2 and Rb1 have strong binding activities to the caspase-3,as well as ginsenoside Rb2 to the nuclear receptor subfamily 3 group C member 1.Conclusion:This study showed that SZDP might act through multiple chemical constituents and targets against coronary heart disease.

Effects of compound danshen dripping pills on the levels of serum inflammatory factors, brain natriuretic peptide and blood lipid in CABG postoperative patients

Objective:To explore the effects of compound danshen dripping pills on the levels of serum inflammatory factors,brain natriuretic peptide(BNP)and blood lipid in CABG postoperative patients.Methods:156 cases of patients who were given CABG from January 2015 to January 2018 in Baogang Hospital were chosen and randomly divided into the observation group(n=78)and the control group(n=78).Both groups were given conventional drugs,simultaneously,the observation group was given compound danshen dripping pills.The treatment lasted 3 months.The clinical efficacy was compared between two groups of patients,and the levels of serum inflammatory factors,plasma BNP and blood lipid before and after treatment in two groups of patients were detected in order to make a comparison in the incidence of adverse cardiac events between two groups of patients.Results:After treatment,the total effective rate of treatment in the observation group was significantly higher than that in the control group;in the two groups,the levels of serum interleukin-6(IL-6),interleukin-8(IL-8),C-reactive protein and plasma BNP after treatment were obviously lower than those before treatment,and these indicators in the observation group were lower than those in the control group(p<.05);the levels of TG,TC and LDL-C in two groups were obviously lower(p<.05)with the level of HDL-C significantly higher(all p<.05),and the descending or ascending range of each indicator in the observation group was obviously larger than that in the control group(p<.05);in the follow-up visit,the incidence of adverse cardiac events in the observation group of patients was significantly lower than that in the control group of patients(p<.05).Conclusions:Compound danshen dripping pills can effectively reduce the levels of serum inflammatory factors and BNP,regulate blood lipid metabolism and reduce the incidence of adverse cardiac events in CABG postoperative patients.

Effect of Guanxin Danshen Dripping Pills on Coronary Heart Disease Comorbid with Depression or Anxiety: The ADECODE-Real World Study

Objective: To evaluate the efficacy of Guanxin Danshen Dripping Pill(GXDSDP) in treating anxiety and depression in patients with coronary heart disease(CHD). Methods: A total of 1,428 patients diagnosed with CHD screened for anxiety, depression, and quality of life(QOL) at baseline received 0.4 g of GXDSDP treatment 3 times per day and returned for monthly reassessment. Patients were recruited after stable treatment for CHD and received assessment of General Anxiety Disorder-7(GAD-7), Patient Health Questionnaire-9(PHQ-9), and Seattle Angina Questionnaire(SAQ) for evaluating anxiety, depression, and QOL.Patients were followed up 3 times, once every 4 weeks, during outpatient visits for 12 weeks. Results: At the third follow-up(F3), the anxiety symptom of 63.79%(673/1,055) of the patients improved to sub-clinical level, and the GAD-7 score improved significantly(8.11 vs. 3.87, P<0.01);57.52%(585/1,017) patients' depressive symptoms improved to sub-clinical level, with a significant improvement in PHQ-9 score(8.69 vs. 4.41, P<0.01) at F3. All aspects of QOL significantly improved at the end of treatment compared to those at baseline(all P<0.01) as assessed by SAQ: physical limitation(31.17 vs. 34.14), anginal stability(2.74 vs. 4.14), anginal frequency(8.16vs. 9.10), treatment satisfaction(13.43 vs. 16.29), and disease perception(8.69 vs. 11.02). Conclusions: A fixed dosage of GXDSDP may be a potential treatment option for CHD patients comorbid with anxiety or depression.(Registration No. ChiCTR2100051523)

Anti-asthmatic mechanism of the Huashanshen dripping pill via suppressing contraction of the airway smooth muscle

Background:The Huashanshen(HSS)dripping pill has been widely used in asthma for a long time in China.However,the relaxant mechanism of HSS is not well understood.Methods:In this report,high performance liquid chromatography coupled with quadrupole time-of-flight mass spectrometry was used to identify the constituents in rat plasma after oral administration of HSS.Ovalbumin-sensitized allergic asthma and isolated trachea were studied for the anti-asthmatic mechanism of HSS.Results:D-anisodamine,L-anisodamine,scopolamine and atropine were detected in the rat plasma containing HSS.It was clear that the HSS inhibited the release of inflammatory mediators,regulated the balance of T-helper 1 and T-helper 2 to reduce the airway inflammation,and relaxed the tracheal smooth muscle by controlling the KCa channel,Ca^(2+)influx and release to reduce the airway hyperresponsiveness.Conclusion:Atropine,anisodamine and scopolamine might be active compounds of HSS which inhibited the release of inflammatory mediators,regulated the balance of Th1/Th2,and relaxed the tracheal smooth muscle to reduce airway hyperresponsiveness.

Qishen Yiqi Dripping Pills for Cardiovascular Diseases: Effects and Mechanisms

Qishen Yiqi Dripping Pills(QSYQ) is a compound of Chinese medicine, which has been used to treat coronary heart disease and cardiac dysfunction. Its natural components include astragaloside Ⅳ, flavonoids, danshensu, protocatechualdehyde, salvianolic acid B, salvianolic acid A, ginsenosides Rg1, ginsenosides Rb1, and essential oils, etc. It exerts effects of nourishing qi and promoting blood circulation to relieve pain. In this review, the bioactive components of QSYQ and its effects for treating cardiovascular diseases and possible mechanism were summarized, providing references for further study and clinical application of QSYQ.

Effects of Compound Danshen Dripping Pills on Ventricular Remodeling and Cardiac Function after Acute Anterior Wall ST-Segment Elevation Myocardial Infarction(CODE-AAMI):Protocol for a Randomized Placebo-Controlled Trial

Background:Ventricular remodeling after acute anterior wall ST-segment elevation myocardial infarction(AAMI)is an important factor in occurrence of heart failure which additionally results in poor prognosis.Therefore,the treatment of ventricular remodeling needs to be further optimized.Compound Danshen Dripping Pills(CDDP),a traditional Chinese medicine,exerts a protective effect on microcirculatory disturbance caused by ischemia-reperfusion injury and attenuates ventricular remodeling after myocardial infarction.Objective:This study is designed to evaluate the efficacy and safety of CDDP in improving ventricular remodeling and cardiac function after AAMI on a larger scale.Methods:This study is a multi-center,randomized,doubleblind,placebo-controlled,parallel-group clinical trial.The total of 268 patients with AAMI after primary percutaneous coronary intervention(pPCI)will be randomly assigned 1:1 to the CDDP group(n=134)and control group(n=134)with a follow-up of 48 weeks.Both groups will be treated with standard therapy of ST-segment elevation myocardial infarction(STEMI),with the CDDP group administrating 20 tablets of CDDP before pPCI and 10 tablets 3 times daily after pPCI,and the control group treated with a placebo simultaneously.The primary endpoint is 48-week echocardiographic outcomes including left ventricular ejection fraction(LVEF),left ventricular end-diastolic volume index(LVEDVI),and left ventricular end-systolic volume index(LVESVI).The secondary endpoint includes the change in N terminal pro-B-type natriuretic peptide(NT-proBNP)level,arrhythmias,and cardiovascular events(death,cardiac arrest,or cardiopulmonary resuscitation,rehospitalization due to heart failure or angina pectoris,deterioration of cardiac function,and stroke).Investigators and patients are both blinded to the allocated treatment.Discussion:This prospective study will investigate the efficacy and safety of CDDP in improving ventricular remodeling and cardiac function in patients undergoing pPCI for a first AAMI.Patients in the CDDP group will be compared with those in the control group.If certified to be effective,CDDP treatment in AAMI will probably be advised on a larger scale.(Trial registration No.NCT05000411)

麝香黄芪复方滴丸含药血清促进骨髓间充质干细胞增殖分化

背景:骨髓间充质干细胞(bone marrow mesenchymal stem cells,BMSCs)已被广泛用于治疗神经系统疾病,但由于血脑屏障的限制以及干细胞在受损部位存活率、分化率低,导致治疗效果有限。目的:探讨麝香黄芪复方滴丸含药血清对BMSCs增殖、迁移和向星形胶质细胞分化的影响。方法:SD雄性大鼠连续灌胃麝香黄芪复方滴丸5 d后进行腹主动脉取血,分离血清备用。采用CCK-8法检测体积分数5%,10%,20%含药血清对BMSCs增殖的影响;划痕实验观察体积分数10%含药血清对BMSCs横向迁移的影响;Transwell小室培养BMSCs,用结晶紫染色和DAPI核染色观察体积分数10%含药血清对BMSCs纵向迁移的影响;用含体积分数10%含药血清的诱导液或与星形胶质细胞共培养观察BMSCs向星形胶质细胞分化情况。结果与结论:①体积分数10%和20%含药血清在第2,3天促进细胞增殖更明显,且两种体积分数无统计学差异;②在划痕30,48 h时,10%含药血清组BMSCs迁移量显著高于对照组;③10%含药血清组BMSCs穿过Transwell小室滤过膜的数量高于对照组;④体积分数10%含药血清可能促进BMSCs向星形胶质细胞方向分化,但分化作用较弱,星形胶质细胞能进一步促进含药血清诱导BMSCs向星形胶质细胞方向分化;⑤结果表明,体积分数10%含药血清能促进BMSCs体外增殖、迁移;与星形胶质细胞共培养可能促进BMSCs向星形胶质细胞方向分化。

瑞舒伐他汀联合芪参益气滴丸治疗高血压病合并冠状动脉粥样硬化性心脏病疗效及对动脉斑块的影响

目的探讨瑞舒伐他汀联合芪参益气滴丸治疗高血压病合并冠状动脉粥样硬化性心脏病的疗效及对动脉斑块的影响。方法选择2021年1月—2021年12月120例高血压病合并冠状动脉粥样硬化性心脏病患者作为研究对象,采用随机数字法平均分为观察组与对照组,两组患者均给予抗血小板聚集及瑞舒伐他汀稳定斑块等治疗措施,观察组在此基础上联合芪参益气滴丸治疗。比较两组患者临床疗效,心功能、血脂水平、颈动脉斑块及不良反应发生情况。结果观察组总有效率明显高于对照组(P<0.05)。随之治疗时间延长,两组患者左心射血分数(left ventricular ejection fractions,LVEF)及左心室收缩末内径(left ventricular end-diastolic dimension,LVEDD)均逐渐改善(P<0.05);治疗后14 d、3月观察组LVEF及LVEDD均高于对照组(P<0.05)。两组患者治疗后甘油三酯、血清总胆固醇、低密度脂蛋白胆固醇、同型半胱氨酸、C-反应蛋白均逐渐改善(P<0.05);治疗后3个月、6个月观察组甘油三酯、血清总胆固醇、低密度脂蛋白胆固醇、同型半胱氨酸、C-反应蛋白低于对照组(P<0.05)。两组患者治疗后颈动脉内中膜厚度(carotid intima-media thickness,IMT)及不稳定斑块比例逐渐降低(P<0.05);治疗后3个月、6个月观察组IMT急不稳定斑块比例低于对照组(P<0.05)。两组不良反应发生率比较差异无统计学意义(P>0.05)。结论瑞舒伐他汀联合芪参益气滴丸可以更好地促进高血压病伴颈动脉硬化急性心肌梗死患者恢复,更快使血脂异常达标,更有效地抑制颈动脉不稳定斑块形成,且并未增加不良反应。

芪参益气滴丸联合重组人脑利钠肽治疗射血分数保留的心力衰竭的临床研究

目的:探讨芪参益气滴丸联合重组人脑利钠肽治疗射血分数保留的心力衰竭(HFpEF)的临床效果。方法:选择2023年1—10月九江市第一人民医院收治的69例HFpEF患者。采用随机数字法分为A组、B组与C组,各23例。A组采用抗心力衰竭常规治疗;B组在A组基础上给予芪参益气滴丸治疗,C组在B组基础上给予注射用重组人脑利钠肽治疗。比较三组治疗前后左房径(LA)、左室射血分数(LVEF)、左室短轴缩短率(LVFS)、舒张早期二尖瓣峰值流速及舒张末期二尖瓣峰值流速比值(E/A)、血清氨基末端-B型脑钠肽前体(NT-proBNP)及6分钟步行试验(6MWT)结果,记录三组用药期间不良反应发生率及再住院率。结果:治疗前、治疗6周后,三组LA比较,差异均无统计学意义(P>0.05);治疗6周后,三组NT-proBNP均低于治疗前,LVEF、LVFS、E/A、6MWT均高于治疗前,同时,C组NT-proBNP低于A组与B组,LVEF、LVFS、E/A、6MWT均高于A组与B组,差异均有统计学意义(P<0.05)。三组不良反应发生率比较,差异无统计学意义(P>0.05)。三组再住院率比较,差异有统计学意义(P<0.05);C组再住院率低于A组与B组,差异均有统计学意义(P<0.05)。结论:芪参益气滴丸联合重组人脑利钠肽治疗可有效改善HFpEF患者心功能,提高患者步行能力,降低再住院率,安全性高。

复方丹参滴丸联合阿托伐他汀钙治疗慢性心力衰竭临床观察

目的探讨复方丹参滴丸联合阿托伐他汀钙对慢性心力衰竭(congestive heart failure,CHF)患者心功能及细胞因子的影响。方法选取2020年8月—2022年8月就诊于济宁市中医院CHF患者92例进行研究,按照随机数字表法分为2组,各46例。对照组予以阿托伐他汀钙片进行治疗,观察组在对照组基础上采用复方丹参滴丸进行治疗,于治疗3个月后评估。对比2组临床疗效、心功能、细胞因子、血管活性物质、不良反应。结果观察组治疗总有效率(95.65%)高于对照组(80.43%),差异有统计学意义(P<0.05)。治疗前2组心功能、细胞因子、血管活性物质对比,差异无统计学意义(P>0.05);与对照组对比,观察组治疗后左室射血分数(left ventricular ejection fractions,LVEF)高,左室舒张末期内径(left ventricular end diastolic diameter,LVEDD)、左室收缩末期内径(left ventricular end systolic diameter,LVESD)低,6 min步行距离(six minute walk distance,6MWD)长,可溶性生长刺激表达基因2蛋白(soluble growth stimulation expression gene 2 protein,sST2)、半乳糖凝集素-3(galectin-3)水平均低,内皮素-1(endothelin-1,ET-1)、血管紧张素Ⅱ(angiotensinⅡ,AngⅡ)、脑利钠肽(brain natriuretic peptide,BNP)水平均低(P<0.05)。观察组不良反应(13.04%)与对照组(10.87%)对比,差异无统计学意义(P>0.05)。结论CHF患者经复方丹参滴丸与阿托伐他汀钙治疗后心功能得到显著改善,且血清细胞因子水平趋于正常,血管活性物质生成有效一致,且安全性高。

一测多评法测定冰川滴丸中6个成分含量

目的 建立同时测定冰川滴丸中6个成分含量的一测多评法。方法 色谱柱为Waters Symmetry C18柱(250 mm×4.6 mm,5μm),流动相为乙腈-0.5%冰醋酸溶液(梯度洗脱),流速为1.0 mL/min,检测波长为285 nm(肉桂酸)、330 nm(阿魏酸和藁本内酯)、430 nm(姜黄素、去甲姜黄素、双去甲姜黄素),进样量为10μL。以肉桂酸为内参物,计算阿魏酸、藁本内酯、姜黄素、去甲姜黄素、双去甲姜黄素的相对校正因子,并与外标法含量测定结果进行比较。结果 阿魏酸、藁本内酯、肉桂酸、姜黄素、去甲姜黄素、双去甲姜黄素的进样量分别在0.025 86~0.142 8μg、0.275 2~2.752μg、0.045 4~0.454μg、0.178 8~1.788μg、0.063 6~0.636μg、0.057 2~0.572μg范围内与峰面积积分值线性关系良好(R2=0.999 9,n=6);精密度、稳定性、重复性试验结果的RSD均小于3.0%(n=6);平均加样回收率分别为96.85%,99.54%,99.75%,99.34%,98.65%,100.44%,RSD分别为1.38%,2.32%,2.82%,2.56%,2.91%,1.46%(n=6)。相对校正因子分别为0.177 5,0.225 6,0.711 2,0.903 5,1.033 6。各成分一测多评法的含量测定结果与外标法接近。结论 该方法操作简便、结果准确、重复性好,可用于同时测定冰川滴丸制剂中6个成分的含量。

复方丹参滴丸抑制活性氧介导的内皮细胞损伤机制

目的探讨复方丹参滴丸抑制活性氧介导的内皮细胞损伤的机制。方法使用过氢化氢(H_(2)O_(2))构建内皮细胞损伤模型,将细胞分为正常组、模型组、复方丹参滴丸(50、100、150μg/mL)组,CCK-8检测细胞增殖情况,LDH试剂盒及ATP试剂盒检测细胞毒性及ATP产生,比色法检测内皮细胞MDA含量及SOD活力;ROS荧光探针检测细胞中ROS含量;Western blot及实时荧光定量PCR检测各组细胞中Bcl-2、Bax及Cleaved caspase-3的蛋白及mRNA表达情况。在上述模型的基础上使用ROS清除剂(NAC)构建ROS清除模型,将细胞分为正常组,H_(2)O_(2)组,H_(2)O_(2)+复方丹参100μg/mL组、H_(2)O_(2)+复方丹参100μg/mL+NAC组,免疫荧光探针、CCK-8、LDH及ATP试剂盒、比色法检测细胞ROS、增殖、毒性、ATP、MDA、SOD的含量及活力;Western blot及实时荧光定量PCR检测凋亡蛋白及mRNA表达情况。结果H_(2)O_(2)刺激后,细胞增殖被抑制,细胞毒性增强,ROS及MDA表达上调,ATP及SOD表达下调,Bcl-2表达下调,Bax及Cleaved caspase-3表达下调,复方丹参滴丸干预后可逆转内皮细胞损伤,以100μg/mL剂量组最显著。ROS清除剂抑制ROS的产生,并减弱100μg/mL复方丹参滴丸逆转内皮细胞损伤作用。结论复方丹参滴丸可逆转氧化应激产生的内皮细胞损伤,此作用可能是通过抑制ROS/Bcl-2/Bax信号通路实现的。

他汀联合DSP治疗CHD-HLP效果的Meta分析

运用Meta分析,探讨他汀联合复方丹参滴丸(DSP)治疗冠心病合并高脂血(CHD-HLP)患者的疗效。结果表明:联合治疗CHD-HLP,(1)血脂水平,TG效应值SMD为-1.71,TC为-1.30,LDL-C为-0.81、HDL-C为0.99;(2)心功能,CI的SMD为0.62、CO为0.84,以上指标均有统计学意义。结论表明:联合治疗比常规他汀治疗更具降脂、提高心功能等优势。

复方丹参滴丸联合美托洛尔治疗慢性心力衰竭合并阵发性房颤患者的效果

目的:观察复方丹参滴丸联合美托洛尔治疗慢性心力衰竭(CHF)合并阵发性房颤(PAF)患者的效果。方法:回顾性分析2021年1月至2023年3月该院收治的150例CHF合并PAF患者的临床资料,按照治疗方法不同将其分为研究组与对照组各75例。对照组口服琥珀酸美托洛尔缓释片治疗,研究组在对照组基础上口服复方丹参滴丸治疗。比较两组临床疗效,治疗前后临床症状(心率、房颤发作次数和房颤发作持续时间)、心肌损伤标志物[肌酸激酶同工酶(CK-MB)、生长分化因子15(GDF-15)、N末端脑钠肽前体(NT-proBNP)]水平、血管内皮功能指标[内皮素-1(ET-1)、同型半胱氨酸(Hcy)]水平,以及不良反应发生率。结果:研究组治疗总有效率为92.00%(69/75),高于对照组的80.00%(60/75),差异有统计学意义(P<0.05);治疗后,研究组心率低于对照组,房颤发作次数少于对照组,房颤发作持续时间短于对照组,差异均有统计学意义(P<0.05);研究组CK-MB、NT-proBNP、GDF-15、ET-1、Hcy水平均低于对照组,差异有统计学意义(P<0.05);两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:复方丹参滴丸联合美托洛尔治疗CHF合并PAF患者效果显著,可减轻房颤症状,降低心率,减轻心肌损伤,保护血管内皮功能,效果优于单用美托洛尔治疗。

Compound Danshen Dripping Pill inhibits hypercholesterolemia/atherosclerosis-induced heart failure in ApoE and LDLR dual deficient mice via multiple mechanisms

Heart failure is the leading cause of death worldwide.Compound Danshen Dripping Pill(CDDP)or CDDP combined with simvastatin has been widely used to treat patients with myocardial infarction and other cardiovascular diseases in China.However,the effect of CDDP on hypercholesterolemia/atherosclerosis-induced heart failure is unknown.We constructed a new model of heart failure induced by hypercholesterolemia/atherosclerosis in apolipoprotein E(ApoE)and LDL receptor(LDLR)dual deficient(ApoE^(–/–)LDLR^(–/–))mice and investigated the effect of CDDP or CDDP plus a low dose of simvastatin on the heart failure.CDDP or CDDP plus a low dose of simvastatin inhibited heart injury by multiple actions including anti-myocardial dysfunction and anti-fibrosis.Mechanistically,both Wnt and lysine-specific demethylase 4A(KDM4A)pathways were significantly activated in mice with heart injury.Conversely,CDDP or CDDP plus a low dose of simvastatin inhibited Wnt pathway by markedly up-regulating expression of Wnt inhibitors.While the anti-inflammation and anti-oxidative stress by CDDP were achieved by inhibiting KDM4A expression and activity.In addition,CDDP attenuated simvastatin-induced myolysis in skeletal muscle.Taken together,our study suggests that CDDP or CDDP plus a low dose of simvastatin can be an effective therapy to reduce hypercholesterolemia/atherosclerosis-induced heart failure.